Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus recommendation of “Buy” by the ten ratings firms that are presently covering the stock, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $6.60.

A number of equities analysts have commented on TSHA shares. BMO Capital Markets initiated coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They issued an “outperform” rating and a $5.00 price objective for the company. Piper Sandler decreased their price objective on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday, July 1st. Jefferies Financial Group reissued a “buy” rating and set a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, June 20th.

Insider Buying and Selling

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the transaction, the insider now owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $413,000. Privium Fund Management B.V. purchased a new position in Taysha Gene Therapies in the second quarter worth $213,000. Principal Financial Group Inc. acquired a new position in shares of Taysha Gene Therapies during the second quarter worth $48,000. Bank of New York Mellon Corp purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at $1,018,000. Finally, Quantum Private Wealth LLC boosted its position in shares of Taysha Gene Therapies by 4.6% in the 2nd quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock worth $1,636,000 after purchasing an additional 32,000 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

Shares of Taysha Gene Therapies stock opened at $2.10 on Monday. The stock has a 50 day moving average of $2.77 and a 200 day moving average of $2.53. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. Taysha Gene Therapies has a 12 month low of $0.66 and a 12 month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. The business had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. During the same period in the prior year, the firm earned ($0.28) EPS. As a group, equities analysts expect that Taysha Gene Therapies will post -0.41 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.